Introduction

Irritable Bowel Syndrome (IBS) is one of the most prevalent functional gastrointestinal disorders encountered in both primary care and gastroenterology practice, affecting an estimated 10 to 15 percent of the global adult population. Despite its high prevalence and significant impact on quality of life, IBS lacks a reliable biomarker or structural abnormality that can serve as a definitive diagnostic standard. For this reason, clinicians have long relied on symptom-based classification systems to identify the condition and guide management.

The Rome III Diagnostic Criteria, published in 2006 by the Rome Foundation, represented a major refinement in the symptom-based approach to diagnosing IBS. Building on earlier iterations (Rome I in 1992 and Rome II in 1999), the Rome III criteria provided tighter definitions of symptom frequency, a clearer temporal framework, and a standardized subtyping system tied to the Bristol Stool Form Scale. These criteria became the worldwide standard for IBS diagnosis in clinical trials and routine practice for over a decade, until they were superseded by the Rome IV criteria in 2016.

Understanding the Rome III criteria remains clinically important. A large body of landmark IBS research, including pivotal drug approval trials, was conducted under Rome III definitions. Familiarity with these criteria is therefore essential for interpreting the evidence base and for settings where Rome IV adoption is not yet complete.

Historical Evolution of IBS Diagnostic Criteria

Before the Rome process, IBS was diagnosed primarily by exclusion, requiring an extensive and often costly battery of tests to rule out organic disease. The Manning Criteria (1978) were among the earliest attempts to define IBS by positive symptom features, identifying six symptoms that distinguished IBS from organic bowel disease. While influential, the Manning Criteria lacked formal frequency or duration thresholds and showed variable sensitivity and specificity across populations.

The Rome I criteria (1992) introduced the concept of a standardized, consensus-derived, symptom-based definition for functional gastrointestinal disorders, including IBS. Rome II (1999) further refined the criteria by specifying that symptoms should be present for at least 12 weeks (not necessarily consecutive) in the preceding 12 months and introduced the term "discomfort" alongside pain to capture the full spectrum of abdominal sensations reported by IBS patients.

Rome III (2006) continued this evolution by changing the frequency threshold from "at least 12 weeks in 12 months" to "at least 3 days per month in the last 3 months." This shift was intended to simplify clinical application while still ensuring that transient symptoms would not be mislabeled as IBS. Rome III also formalized the IBS subtype system based on predominant stool pattern, replacing loosely defined descriptors with explicit criteria linked to the Bristol Stool Form Scale.

The Rome III Diagnostic Criteria for IBS

The Rome III definition of IBS requires that the patient has experienced recurrent abdominal pain or discomfort at least 3 days per month in the last 3 months, with symptom onset at least 6 months prior to diagnosis. In addition, the abdominal pain or discomfort must be associated with two or more of the following three features:

1. Improvement with defecation: The abdominal pain or discomfort improves or resolves following a bowel movement.
2. Onset associated with a change in frequency of stool: Episodes of pain or discomfort coincide with an increase or decrease in how often the patient has bowel movements.
3. Onset associated with a change in form (appearance) of stool: Episodes of pain or discomfort coincide with a change in stool consistency, such as a shift from normal to loose/watery or from normal to lumpy/hard.

The Rome III committee specifically noted that "discomfort" refers to an uncomfortable sensation not described as pain. This inclusive phrasing was adopted to capture patients whose predominant symptom is bloating, pressure, or a vague sense of abdominal unease rather than frank pain. In research settings, the presence of pain (rather than discomfort alone) was often required for more stringent case identification.

Mandatory Temporal Requirements

Two temporal thresholds must be satisfied before the diagnostic criteria can be applied:

• Current symptom activity: Recurrent abdominal pain or discomfort on at least 3 days per month during the most recent 3-month period.
• Chronicity: Symptom onset at least 6 months before the date of diagnosis. This requirement ensures that the clinician is identifying a chronic, recurring pattern rather than an acute, self-limited episode of abdominal pain.

Together, these two temporal gates establish both the recency and the chronicity of the symptom pattern. A patient who has experienced abdominal pain for only 4 months, even if it occurs daily, would not satisfy the 6-month onset requirement. Conversely, a patient with a 2-year history of intermittent symptoms who has had pain on only 1 day per month over the last 3 months would not meet the frequency threshold.

Associated Features (2 of 3 Required)

The three associated features link the abdominal pain or discomfort to defecatory events or stool characteristics. At least two of the three must be present for criteria fulfillment.

Improvement with Defecation

This feature captures the observation that many IBS patients experience partial or complete relief of abdominal pain after passing stool. It reflects the role of altered colonic motility and visceral hypersensitivity in IBS pathophysiology. A subset of patients, however, may report worsening pain with defecation, particularly those with constipation-predominant IBS. The Rome III criteria use "improvement" rather than "relief" to acknowledge that the response may be partial.

Onset Associated with a Change in Stool Frequency

Patients frequently report that their abdominal pain coincides with a noticeable increase or decrease in bowel movement frequency. An increase may manifest as multiple loose stools per day (characteristic of IBS-D), while a decrease may present as infrequent, difficult-to-pass stools (characteristic of IBS-C). The criterion requires a temporal association between the onset of pain and the change in frequency, not merely the coexistence of pain and altered bowel habits at any point.

Onset Associated with a Change in Stool Form

This feature focuses on the consistency and appearance of stool, as classified by the Bristol Stool Form Scale. Patients may describe stools that have become harder, lumpier, looser, or more watery in temporal association with their abdominal pain episodes. Like the frequency criterion, the important element is the temporal link between pain onset and the change in stool form.

IBS Subtype Classification

The Rome III criteria introduced a formalized subtyping system for IBS that is based on the patient's predominant stool pattern, assessed using the Bristol Stool Form Scale (BSFS). The BSFS classifies stool into seven types, ranging from Type 1 (separate hard lumps, like nuts) to Type 7 (watery, no solid pieces). For IBS subtyping, Types 1 and 2 are considered hard/lumpy and Types 6 and 7 are considered loose/watery.

Subtype	Name	Stool Pattern Definition
IBS-C	Constipation-predominant	Hard or lumpy stools (BSFS 1-2) in ≥25% of bowel movements and loose or watery stools (BSFS 6-7) in <25% of bowel movements
IBS-D	Diarrhea-predominant	Loose or watery stools (BSFS 6-7) in ≥25% of bowel movements and hard or lumpy stools (BSFS 1-2) in <25% of bowel movements
IBS-M	Mixed	Hard or lumpy stools (BSFS 1-2) in ≥25% of bowel movements and loose or watery stools (BSFS 6-7) in ≥25% of bowel movements
IBS-U	Unsubtyped	Insufficient stool form abnormality to meet criteria for IBS-C, IBS-D, or IBS-M

Subtyping is performed only after a positive IBS diagnosis has been established. The classification should ideally be based on a stool diary maintained over at least a 2-week period, as patient recall of stool form is unreliable. Subtype assignment is clinically relevant because pharmacological treatment selection often depends on the predominant bowel pattern. For example, osmotic laxatives and secretagogues are first-line options for IBS-C, while loperamide and bile acid sequestrants may be preferred in IBS-D.

It is important to recognize that IBS subtypes are not fixed. A substantial proportion of patients transition between subtypes over time, most commonly between IBS-C and IBS-M or between IBS-D and IBS-M. This fluidity underscores the need for periodic reassessment of the predominant stool pattern, particularly when adjusting therapy.

The Bristol Stool Form Scale in Context

The Bristol Stool Form Scale (BSFS) is a visual descriptive tool developed by Heaton and Lewis at the University of Bristol. It categorizes human feces into seven types based on form and consistency:

1. Type 1: Separate hard lumps, like nuts (hard to pass)
2. Type 2: Sausage-shaped but lumpy
3. Type 3: Like a sausage but with cracks on its surface
4. Type 4: Like a sausage or snake, smooth and soft
5. Type 5: Soft blobs with clear-cut edges (passed easily)
6. Type 6: Fluffy pieces with ragged edges, a mushy stool
7. Type 7: Watery, no solid pieces (entirely liquid)

For Rome III IBS subtyping, Types 1 and 2 represent the constipation end of the spectrum, while Types 6 and 7 represent the diarrhea end. Types 3 through 5 are considered normal. The BSFS provides a simple, reproducible method for patients to communicate stool consistency to their clinicians without the ambiguity that accompanies purely verbal descriptions.

Epidemiology of IBS Under Rome III Criteria

Population-based studies using Rome III criteria have consistently found IBS prevalence rates between 10 and 15 percent in Western countries, with somewhat lower rates (5 to 10 percent) reported in Asian populations. Women are diagnosed approximately 1.5 to 2 times more frequently than men in most studies, although this sex ratio may partly reflect differences in healthcare-seeking behavior rather than true differences in disease prevalence.

IBS can present at any age but most commonly manifests between the ages of 20 and 40. The condition accounts for up to 12 percent of primary care visits and 25 to 50 percent of gastroenterology referrals. Direct and indirect costs associated with IBS are substantial, including healthcare expenditures, lost workplace productivity, and diminished quality of life. Multiple studies have demonstrated that IBS imposes a quality-of-life burden comparable to that of inflammatory bowel disease, diabetes mellitus, and chronic kidney disease.

Pathophysiology and Relevance to Rome III Criteria

IBS is now understood as a disorder of gut-brain interaction, reflecting a complex interplay of peripheral and central mechanisms. While the Rome III criteria are purely symptom-based and do not require any understanding of pathophysiology for their application, awareness of the underlying mechanisms helps explain why the chosen criteria (pain, defecation-related features, stool form changes) are clinically useful diagnostic anchors.

Visceral Hypersensitivity

A core feature of IBS is enhanced perception of visceral stimuli, known as visceral hypersensitivity. Studies using rectal balloon distension have shown that IBS patients report pain and discomfort at significantly lower distension volumes and pressures than healthy controls. This heightened sensitivity to normal physiological events (such as colonic distension during gas transit or stool passage) directly underlies the cardinal symptom of recurrent abdominal pain.

Altered Gastrointestinal Motility

Abnormalities in colonic and small bowel motility are well documented in IBS. Patients with IBS-D tend to exhibit accelerated colonic transit, producing loose, frequent stools. Patients with IBS-C typically demonstrate delayed colonic transit, resulting in hard, infrequent stools. These motility disturbances correspond directly to the Rome III associated features related to changes in stool frequency and form.

Brain-Gut Axis Dysregulation

Functional neuroimaging studies have revealed altered processing of visceral afferent signals in the central nervous system of IBS patients. Areas of the brain involved in pain modulation, emotional processing, and autonomic regulation (including the anterior cingulate cortex, insula, and prefrontal cortex) show abnormal activation patterns. This central dysregulation contributes to the amplification of gut sensations and helps explain the strong association between IBS and psychological comorbidities such as anxiety and depression.

Intestinal Immune Activation and Microbiome Alterations

Low-grade mucosal inflammation, increased mast cell density, and alterations in the intestinal microbiome have been described in subsets of IBS patients. Post-infectious IBS, which develops after an episode of acute gastroenteritis, provides the clearest evidence for an immune-mediated component. These findings, while not captured by the Rome III criteria themselves, have expanded the understanding of IBS as a heterogeneous condition with multiple potential pathogenic pathways.

Clinical Application of the Rome III Criteria

The Rome III criteria are designed for use in clinical settings where organic gastrointestinal disease has been reasonably excluded based on the clinical presentation and appropriate baseline testing. They are intended as a positive diagnostic framework, allowing clinicians to make a confident diagnosis of IBS without exhaustive testing in patients who present with a characteristic symptom pattern and no alarm features.

Step-by-Step Clinical Assessment

1. Screen for alarm features: Before applying the Rome III criteria, evaluate for red-flag symptoms that suggest organic pathology. These include unintentional weight loss, rectal bleeding, nocturnal symptoms that awaken the patient from sleep, progressive worsening of symptoms, family history of colorectal cancer or inflammatory bowel disease, anemia, fever, and new onset of symptoms after age 50. The presence of any alarm feature warrants further investigation before a diagnosis of IBS is assigned.
2. Assess the frequency criterion: Determine whether the patient has experienced recurrent abdominal pain or discomfort on at least 3 days per month during the last 3 months.
3. Confirm the onset criterion: Verify that the initial onset of these symptoms occurred at least 6 months before the date of evaluation.
4. Evaluate the three associated features: Ask the patient whether the abdominal pain or discomfort (a) improves with defecation, (b) is associated with a change in stool frequency, and (c) is associated with a change in stool form. At least two of the three must be endorsed.
5. Assign the IBS subtype: If the diagnostic criteria are met, classify the patient into IBS-C, IBS-D, IBS-M, or IBS-U based on the predominant stool pattern using the Bristol Stool Form Scale. A prospective stool diary over 2 weeks is recommended for accurate subtyping.

Baseline Investigations

While the Rome III criteria support a positive diagnosis of IBS, most guidelines recommend a limited set of baseline investigations to exclude common mimics. Commonly suggested tests include:

• Complete blood count (to screen for anemia and infection)
• C-reactive protein or erythrocyte sedimentation rate (to screen for inflammatory processes)
• Tissue transglutaminase antibody with total IgA (to screen for celiac disease, which can mimic IBS-D)
• Thyroid function tests (hypothyroidism can mimic IBS-C; hyperthyroidism can mimic IBS-D)
• Fecal calprotectin (to help distinguish IBS from inflammatory bowel disease, particularly in patients under 50 with diarrhea-predominant symptoms)

Colonoscopy is generally not required in young patients (<50 years) who meet Rome III criteria and have no alarm features. In patients over 50, colonoscopy may be indicated for age-appropriate colorectal cancer screening, but IBS itself is not an indication for colonoscopy in the absence of red flags.

Differential Diagnosis

Several conditions can produce symptoms that overlap with the Rome III criteria for IBS. A thorough differential diagnosis is essential to avoid mislabeling organic disease as a functional disorder.

Celiac Disease

Celiac disease is a systemic autoimmune disorder triggered by dietary gluten in genetically susceptible individuals. It can present with abdominal pain, bloating, diarrhea, and altered stool consistency, closely mimicking IBS-D or IBS-M. Serologic screening with tissue transglutaminase IgA antibodies is recommended in all patients with suspected IBS-D, as the prevalence of celiac disease in IBS cohorts is approximately four times higher than in the general population.

Inflammatory Bowel Disease

Crohn's disease and ulcerative colitis can present insidiously with abdominal pain and altered bowel habits before overt inflammatory features (bloody stool, weight loss, extraintestinal manifestations) become apparent. Fecal calprotectin is a useful non-invasive biomarker that can help differentiate IBD from IBS; a level below 50 micrograms per gram has a high negative predictive value for active intestinal inflammation.

Microscopic Colitis

Microscopic colitis (collagenous and lymphocytic colitis) is an increasingly recognized cause of chronic watery diarrhea, particularly in older women. Because the colonic mucosa appears grossly normal on colonoscopy, the diagnosis requires mucosal biopsies. Microscopic colitis should be considered in patients labeled as IBS-D who do not respond to standard IBS therapies.

Small Intestinal Bacterial Overgrowth (SIBO)

SIBO is characterized by excessive bacterial colonization of the small intestine, leading to bloating, abdominal pain, diarrhea, and malabsorption. There is considerable symptom overlap with IBS, and some studies suggest that a subset of IBS patients may have underlying SIBO. Breath testing with glucose or lactulose is used for non-invasive diagnosis, though the sensitivity and specificity of these tests remain debated.

Bile Acid Malabsorption

Bile acid malabsorption (BAM), also known as bile acid diarrhea, is an underdiagnosed cause of chronic diarrhea that may account for a significant proportion of cases previously labeled as IBS-D. The SeHCAT retention test is the reference standard for diagnosis, although empiric trials of bile acid sequestrants (such as cholestyramine or colesevelam) are often used as a practical diagnostic and therapeutic strategy.

Other Conditions

• Lactose intolerance and other carbohydrate malabsorption syndromes can produce bloating, pain, and diarrhea that mimic IBS.
• Endometriosis involving the bowel can cause cyclical abdominal pain and altered bowel habits in women of reproductive age.
• Chronic mesenteric ischemia should be considered in older patients with postprandial pain and weight loss.
• Colorectal neoplasia must be excluded in patients with alarm features or those due for age-appropriate screening.

Supportive Symptoms Not Included in the Formal Criteria

The Rome III working group identified several symptoms that are commonly associated with IBS but were not included in the formal diagnostic criteria due to insufficient discriminatory power. These supportive symptoms can nonetheless strengthen clinical confidence in the diagnosis:

• Abnormal stool frequency (more than 3 per day or fewer than 3 per week)
• Abnormal stool form (lumpy/hard or loose/watery)
• Straining during defecation
• Urgency (having to rush to have a bowel movement)
• Feeling of incomplete evacuation
• Passage of mucus in the stool
• Abdominal bloating or visible distension

While these features are not required for diagnosis, their presence in a patient who also meets the formal Rome III criteria adds further support to an IBS diagnosis.

Psychological Comorbidities and Quality of Life

IBS is strongly associated with psychological comorbidities, including generalized anxiety disorder, major depressive disorder, somatization disorder, and a history of physical or sexual abuse. Up to 60 percent of IBS patients in tertiary care settings have a coexisting psychiatric diagnosis. The relationship between psychological distress and IBS is bidirectional: psychological stress can exacerbate gastrointestinal symptoms through brain-gut axis dysregulation, and chronic gastrointestinal symptoms can precipitate or worsen anxiety and depression.

The impact of IBS on health-related quality of life is significant and often underappreciated. Patients report impairment in physical functioning, social activities, work productivity, emotional well-being, and dietary freedom. Studies using standardized quality-of-life instruments (such as the SF-36 and the IBS-QoL) have consistently shown that IBS patients score significantly lower than population norms and comparably to patients with chronic organic diseases.

Rome III vs. Rome IV: Key Differences

The Rome IV criteria, published in 2016, introduced several notable changes compared to Rome III. Understanding these differences is relevant for interpreting older literature and for clinical settings that may still reference Rome III definitions.

Feature	Rome III (2006)	Rome IV (2016)
Central symptom	Recurrent abdominal pain or discomfort	Recurrent abdominal pain (discomfort removed)
Frequency threshold	≥3 days per month	≥1 day per week
Associated features	Related to defecation, stool frequency, stool form (2 of 3)	Related to defecation, stool frequency, stool form (2 of 3)
Feature wording	"Improvement with defecation"	"Related to defecation" (may improve or worsen)
Temporal requirement	Last 3 months, onset ≥6 months prior	Last 3 months, onset ≥6 months prior
Terminology	Functional gastrointestinal disorder	Disorder of gut-brain interaction
Subtype classification	Based on proportion of abnormal stools among all BMs	Based on proportion of abnormal stools only on days with abnormal BMs

The removal of "discomfort" and the increased frequency threshold (≥1 day per week instead of ≥3 days per month) in Rome IV result in a more restrictive definition that identifies a smaller, more symptomatic cohort. Studies comparing the two criteria sets have shown that Rome IV identifies approximately 50 percent fewer IBS patients than Rome III in the same populations. Patients who meet Rome III but not Rome IV criteria tend to have milder symptoms and lower levels of psychological comorbidity, but they may still benefit from IBS-directed therapy.

Limitations of the Rome III Criteria

While the Rome III criteria represented a significant advance in the standardization of IBS diagnosis, they have several recognized limitations:

• Reliance on subjective symptom reporting: All Rome criteria are inherently dependent on patient self-report, which is subject to recall bias, cultural interpretation of symptoms, and variability in pain thresholds.
• Inclusion of "discomfort": The term "discomfort" is vague and culturally variable. Different patients and different languages interpret "discomfort" in different ways, which may lead to inconsistent application of the criteria across populations. This ambiguity was one of the primary reasons the Rome IV committee removed the term.
• Low frequency threshold: The threshold of at least 3 days per month was criticized as potentially too inclusive, capturing patients with mild, intermittent symptoms that might not warrant a formal IBS diagnosis. This threshold may also capture patients with occasional functional dyspepsia or isolated episodes of dietary intolerance.
• No biomarker integration: The Rome III criteria are purely clinical and do not incorporate any laboratory, imaging, or physiological testing. While this design was intentional (to allow diagnosis without extensive workup), it means the criteria cannot distinguish between IBS and early presentations of organic disease that have not yet developed alarm features.
• Subtype instability: The subtype classifications, while clinically useful at a given point in time, are not stable longitudinal descriptors. Patients frequently transition between subtypes, which complicates treatment planning and research stratification.
• Limited applicability in certain populations: The criteria were developed and validated primarily in Western, adult populations. Their performance in pediatric patients, elderly patients, and diverse cultural settings may differ.

Special Populations

Pediatric Considerations

The Rome III criteria for IBS in children and adolescents differ slightly from the adult criteria. The pediatric definition requires abdominal discomfort or pain associated with two or more of the same three features (improvement with defecation, onset associated with change in stool frequency, onset associated with change in stool form) occurring at least once per week for at least 2 months prior to diagnosis. These modified thresholds account for the difficulty of obtaining reliable symptom histories from younger patients and the different epidemiological patterns of functional bowel disorders in childhood.

Elderly Patients

New-onset IBS symptoms in patients over the age of 50 should be approached with particular caution. While IBS can certainly persist into or develop in later life, the differential diagnosis in this age group broadens considerably to include colorectal neoplasia, microscopic colitis, ischemic colitis, diverticular disease, and medication side effects. A lower threshold for endoscopic evaluation is generally recommended in elderly patients presenting with IBS-like symptoms.

Post-Infectious IBS

Post-infectious IBS (PI-IBS) develops in approximately 10 to 15 percent of individuals following an episode of acute bacterial, viral, or parasitic gastroenteritis. Risk factors for PI-IBS include female sex, younger age, severity and duration of the initial infection, psychological distress at the time of the infection, and concurrent use of antibiotics. PI-IBS patients typically present with an IBS-D phenotype and may have detectable low-grade mucosal inflammation and increased intestinal permeability for months to years after the initial infection. The Rome III criteria can be applied to diagnose PI-IBS, with the additional historical context of a preceding infectious episode.

Implications for Treatment Selection

A positive Rome III IBS diagnosis, combined with subtype classification, guides the initial approach to treatment. Management typically involves a combination of lifestyle modifications, dietary interventions, and pharmacotherapy tailored to the predominant symptom pattern.

General Measures

• Patient education and reassurance regarding the benign nature of IBS
• Regular physical activity, which has been shown to improve IBS symptoms
• Stress management techniques, including cognitive behavioral therapy and gut-directed hypnotherapy
• Dietary modifications such as the low-FODMAP diet, which reduces fermentable carbohydrates that can trigger symptoms
• Adequate hydration and soluble fiber supplementation (e.g., psyllium), particularly for IBS-C

Subtype-Directed Pharmacotherapy

IBS Subtype	First-Line Pharmacotherapy Options
IBS-C	Osmotic laxatives (PEG), linaclotide, lubiprostone, plecanatide
IBS-D	Loperamide, bile acid sequestrants, rifaximin, eluxadoline, alosetron (restricted use)
IBS-M	Antispasmodics, neuromodulators (TCAs, SSRIs), combination approaches
IBS-U	Symptom-directed therapy; reassess subtype over time

Neuromodulators

Tricyclic antidepressants (such as amitriptyline and nortriptyline) at low doses have demonstrated efficacy for global IBS symptom improvement, particularly in IBS-D, through their effects on visceral pain perception and gastrointestinal transit. Selective serotonin reuptake inhibitors (SSRIs) may be preferred in patients with comorbid anxiety or depression, or in IBS-C where the prokinetic effect of SSRIs may be beneficial.

Use in Clinical Trials and Research

The Rome III criteria served as the standard entry criteria for IBS clinical trials from 2006 through approximately 2016. Pivotal trials that led to the approval of several IBS-targeted medications, including linaclotide, lubiprostone, rifaximin, and eluxadoline, used Rome III definitions for patient enrollment. Understanding this is important when interpreting the generalizability of trial results to current clinical practice, where Rome IV criteria may identify a somewhat different (and potentially more severely affected) patient population.

In epidemiological research, the Rome III criteria enabled cross-study comparisons and meta-analyses by providing a uniform diagnostic standard. Large population-based surveys conducted across multiple countries using Rome III criteria have contributed substantially to our understanding of IBS prevalence, natural history, risk factors, and healthcare utilization patterns.

Practical Pearls for Clinical Use

• Apply the Rome III criteria as a positive diagnostic tool, not merely as a diagnosis of exclusion. The criteria are designed to identify a recognizable clinical syndrome.
• Always screen for alarm features before applying the criteria. Red flags mandate further investigation regardless of how well the patient's symptoms fit the Rome III definition.
• Use a stool diary for accurate subtyping. Ask patients to record stool form (using the Bristol Stool Form Scale) and frequency for at least 2 weeks before assigning a subtype.
• Remember that the term "discomfort" in Rome III is intentionally broad. Do not dismiss a patient's symptoms because they describe bloating or pressure rather than pain.
• Reassess the subtype periodically. Patients commonly transition between IBS-C, IBS-D, IBS-M, and IBS-U over time, and treatment should be adjusted accordingly.
• Consider fecal calprotectin and celiac serology as cost-effective baseline tests to increase diagnostic confidence, particularly in patients with diarrhea-predominant symptoms.
• Communicate the diagnosis positively. Explaining to the patient that IBS is a well-recognized medical condition with effective treatments can improve therapeutic engagement and reduce unnecessary healthcare utilization.